Trial · NCT05725200
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
NCT05725200, Phase 2, Recruiting, Oslo University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer. Trials, record NCT05725200. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05725200
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- NCT number
- NCT05725200
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Oslo University Hospital
- Conditions
- Metastatic Colorectal Cancer
- Interventions
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
- First posted
- 2023-02-13
- Last updated
- 2023-02-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pre-Screening: Obtain a combined pharmacogenomic profile which can be used to provide a MTB-nominated treatment | In average of 3 months | Number of participants that obtain a full combined pharmacogenomic profile which can be used to provide an MTB-nominated treatment in the Main Study. |
| Primary | Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC. | Through study completion, in average 6 months | Number of patients who achieve objective response according RECIST 1.1 in the total study population and each study drug cohort of MTB-nominated therapies with drugs not approved or implemented SOC for treatment of mCRC. |
| Secondary | Pre-Screening: To obtain a full combined pharmacogenomic profile from a tumor biopsy that is eligible for treatment decisions in a standard oncology practice. | Through study completion, approximately 4 years | Pre-Screening: Number of participants who achieve a full combined pharmacogenomic profile eligible for treatment decisions either by * An MTB-nominated treatment provided in the Main Study * An MTB-nominated treatment considered as SOC * An MTB-nominated treatment not considered as SOC and not provided in the Main Study * No MTB-nominated treatment suggested |
| Secondary | Main Study: Progression-free survival (PFS) and duration of response (DOR) | Through study completion, approximately 6 months | Progression-free survival (PFS) and duration of response (DOR) by RECIST 1.1, of participants receiving an MTB-nominated anti-cancer therapy, by calculation of number of days, weeks or years. |
| Secondary | Main Study: Overall survival (OS) | Through study completion, approximately 6 months | OS of participants receiving MTB-nominated anti-cancer therapy, defined as the time from first dose of MTB-nominated treatment to date of death from any cause by calculation of number of days, weeks or years. |
| Secondary | Main Study: Safety and tolerability of the different MTB-nominated treatments | Through study completion, approximately 6 months | Register adverse events (AE) in accordance with CTCAE v 5.1 |
| Secondary | Main Study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the prior line(s) SOC treatment. | Through study completion, approximately 6 months | Number of patients who achieve objective response according to RECIST 1.1 from anti-cancer therapy (SOC) in prior lines. |
| Secondary | Main Study: Efficacy of MTB-nominated anti-cancer therapy compared to the efficacy of prior lines SOC treatment. | Through study completion, approximately 6 months. | DOR and PFS by RECIST 1.1 of participants receiving an MTB-nominated treatment and from anti-cancer therapy received in prior lines of SOC in each patient, by calculation of number of days, weeks or years. |
| Secondary | Main study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the next line(s) SOC treatment. | Through study completion, approximately 6 months. | Number of patients who achieve objective response according to RECIST 1.1 from receiving anti-cancer therapy in the next/later lines. |
| Secondary | Main study: Efficacy of an MTB-nominated anti-cancer therapy compared to the efficacy achieved by the next line(s) of SOC treatment. | Through study completion, approximately 6 months. | DOR and PFS by RECIST 1.1 of participants receiving an MTB-nominated treatment and from anti-cancer therapy in the next/later lines of SOC treatment in each patient, by calculation of number of days, weeks or years. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05725200
GET https://conductscience.org/api/trials/v1/NCT05725200/registered